Due to its indispensable role in human NER, including both global genome and transcription-coupled NER sub-pathways, XPA may serve as a potential target for sensitization to cancer chemotherapy (e.g. cisplatin) via manipulation of available nuclear XPA, either at the transcriptional or post-transcriptional level [53], [54], [55]. The gene discussed is XPA; the disease is cancer.